These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37117485)

  • 1. DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice.
    Seo JH; Shin JH; Lee J; Kim D; Hwang HY; Nam BG; Lee J; Kim HH; Cho SR
    Commun Biol; 2023 Apr; 6(1):466. PubMed ID: 37117485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.
    Duarte F; Vachey G; Caron NS; Sipion M; Rey M; Perrier AL; Hayden MR; Déglon N
    Hum Gene Ther; 2023 Sep; 34(17-18):958-974. PubMed ID: 37658843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
    Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
    J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant huntingtin protein induces MLH1 degradation, DNA hyperexcision, and cGAS-STING-dependent apoptosis.
    Sun X; Liu L; Wu C; Li X; Guo J; Zhang J; Guan J; Wang N; Gu L; Yang XW; Li GM
    Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2313652121. PubMed ID: 38498709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
    Alkanli SS; Alkanli N; Ay A; Albeniz I
    Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
    Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
    Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
    Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
    Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
    Choudhury KR; Das S; Bhattacharyya NP
    J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease.
    Yan S; Zheng X; Lin Y; Li C; Liu Z; Li J; Tu Z; Zhao Y; Huang C; Chen Y; Li J; Song X; Han B; Wang W; Liang W; Lai L; Li XJ; Li S
    Nat Biomed Eng; 2023 May; 7(5):629-646. PubMed ID: 36797418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy for Huntington's Disease Using Targeted Endonucleases.
    Dabrowska M; Olejniczak M
    Methods Mol Biol; 2020; 2056():269-284. PubMed ID: 31586354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
    Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
    Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
    Graham RK; Deng Y; Carroll J; Vaid K; Cowan C; Pouladi MA; Metzler M; Bissada N; Wang L; Faull RL; Gray M; Yang XW; Raymond LA; Hayden MR
    J Neurosci; 2010 Nov; 30(45):15019-29. PubMed ID: 21068307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.